CJC-1295 + Ipamorelin: Stack Mechanism in Research

EXOMA Scientific Team · Publicado el 8 de mayo de 2026 · Actualizado el 18 de agosto de 2026

Analysis of the CJC-1295 + Ipamorelin stack in preclinical literature: why they are combined, how their mechanisms differ, and what to look for in the analytical data.

Why they are studied together

CJC-1295 and Ipamorelin act on different but complementary pathways of the somatotropic axis. Combining them in research allows the study of the synergistic pulsatile release of endogenous growth hormone in animal models.

CJC-1295: pharmacological details

CJC-1295 is a modified analog of GHRH (1-29) with amino acid substitutions that prolong its half-life:

• CJC-1295 without DAC: half-life ~30 minutes
• CJC-1295 with DAC (Drug Affinity Complex): half-life ~6-8 days due to albumin binding

For research protocols it is critical to distinguish between the two variants — their experimental applications are distinct.

Ipamorelin: pharmacological details

Ipamorelin is a pentapeptide secretagogue selective for the GHSR-1a receptor. Unlike other GHRPs (GHRP-2, GHRP-6), Ipamorelin is distinguished by:

• Do not stimulate cortisol or prolactin significantly
• Do not stimulate appetite (does not markedly affect the peripheral ghrelin receptor)
• Short half-life (~2 hours)

The concept of synergy

The isolated administration of a secretagogue (Ipamorelin) produces a GH pulse limited by the availability of stored GH. The isolated administration of a GHRH analog (CJC-1295) increases GH synthesis but requires a release stimulus.

Combined, the effect in preclinical literature is 2 to 3 times higher to that of each compound separately in terms of area under the GH curve.

Reconstitution of the stack

Both compounds are reconstituted separately:

CJC-1295 (2 mg) + 2 mL bacteriostatic water = 1 mg/mL Ipamorelin (2 mg) + 2 mL bacteriostatic water = 1 mg/mL

The reconstituted solutions are stored refrigerated and administered separately or mixed in the same syringe at the time of dosing.

Frequency described in the literature

Required purity

For the synergy to be experimentally reproducible, both peptides must meet HPLC ≥99% and a verifiable COA. A lower purity introduces variables that invalidate the experimental model.

References

1. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID 9849822. (animal/in vitro)
2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID 16352683. (human)

Products available at EXOMA

• Ipamorelin